Omicron variants escape the persistent SARS-CoV-2-specific antibody response in 2-year COVID-19 convalescents regardless of vaccination

References

• WHO. WHO Coronavirus (COVID-19) Dashboard. 2022 [cited 2022 October 29]; Available from: https://covid19.who.int/.
   Google Scholar
• Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet. 2020 Nov 14;396(10262):1595–1606.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang L, Sang L, et al. Kinetics of viral load and antibody response in relation to COVID-19 severity. J Clin Invest. 2020 Oct 1;130(10):5235–5244.
   PubMed Web of Science ®Google Scholar
• Sun B, Feng Y, Mo X, et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect. 2020 Dec;9(1):940–948.
   PubMed Web of Science ®Google Scholar
• Huang AT, Garcia-Carreras B, Hitchings MDT, et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nat Commun. 2020 Sep 17;11(1):4704.
   PubMed Web of Science ®Google Scholar
• Padoan A, Sciacovelli L, Basso D, et al. IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: a longitudinal study. Clin Chim Acta. 2020 Aug;507:164–166.
   PubMed Web of Science ®Google Scholar
• Yu S, An J, Liao X, et al. Distinct kinetics of immunoglobulin isotypes reveal early diagnosis and disease severity of COVID-19: a 6-month follow-up. Clin Transl Med. 2021 Mar;11(3):e342.
   PubMed Web of Science ®Google Scholar
• Yang Y, Yang M, Peng Y, et al. Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection. Nat Microbiol. 2022 Mar;7(3):423–433.
   PubMed Web of Science ®Google Scholar
• Li C, Yu D, Wu X, et al. Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan. Nat Commun. 2021 Jul 6;12(1):4144.
   PubMed Web of Science ®Google Scholar
• Choe PG, Hong J, Park J, et al. Persistent antibody responses up to 18 months after mild SARS-CoV-2 infection. J Infect Dis. 2022 Sep 28;226(7):1224–1230.
   PubMed Web of Science ®Google Scholar
• Huang L, Li X, Gu X, et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med. 2022 Sep;10(9):863–876.
   PubMed Web of Science ®Google Scholar
• Macchia A, Ferrante D, Angeleri P, et al. Evaluation of a COVID-19 vaccine campaign and SARS-CoV-2 infection and mortality among adults aged 60 years and older in a middle-income country. JAMA Netw Open. 2021 Oct 1;4(10):e2130800.
   PubMed Web of Science ®Google Scholar
• Cerqueira-Silva T, Andrews JR, Boaventura VS, et al. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study. Lancet Infect Dis. 2022 Jun;22(6):791–801.
   PubMed Web of Science ®Google Scholar
• Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2021 Feb;21(2):73–82.
   PubMed Web of Science ®Google Scholar
• Xu K, Fan C, Han Y, et al. Immunogenicity, efficacy and safety of COVID-19 vaccines: an update of data published by 31 December 2021. Int Immunol. 2022 Jul 2:dxac031.
   PubMed Web of Science ®Google Scholar
• Bar-On YM, Goldberg Y, Mandel M, et al. Protection by a fourth dose of BNT162b2 against omicron in Israel. N Engl J Med. 2022 May 5;386(18):1712–1720.
   PubMed Web of Science ®Google Scholar
• Kamar N, Abravanel F, Marion O, et al. Assessment of 4 doses of SARS-CoV-2 messenger RNA-based vaccine in recipients of a solid organ transplant. JAMA Netw Open. 2021 Nov 1;4(11):e2136030.
   PubMed Web of Science ®Google Scholar
• Teles M, Connolly CM, Frey S, et al. Attenuated response to fourth dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series. Ann Rheum Dis. 2022 May;81(5):738–740.
   PubMed Web of Science ®Google Scholar
• Benotmane I, Bruel T, Planas D, et al. A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients. Kidney Int. 2022 May;101(5):1073–1076.
   PubMed Web of Science ®Google Scholar
• Magen O, Waxman JG, Makov-Assif M, et al. Fourth dose of BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2022 Apr 28;386(17):1603–1614.
   PubMed Web of Science ®Google Scholar
• Zhou X, Cheng L, Wang H, et al. The SARS-CoV-2 inactivated vaccine enhances the broad neutralization against variants in individuals recovered from COVID-19 up to one year. Emerg Microbes Infect. 2022 Dec;11(1):753–756.
   PubMed Web of Science ®Google Scholar
• Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin Infect Dis. 2020 Nov 19;71(16):2027–2034.
   PubMed Web of Science ®Google Scholar
• Yousefi Z, Taheri N, Dargahi M, et al. Long-term persistence of anti-SARS-COV-2 IgG antibodies. Curr Microbiol. 2022 Feb 12;79(4):96.
   PubMed Web of Science ®Google Scholar
• Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med. 2007 Nov 8;357(19):1903–1915.
   PubMed Web of Science ®Google Scholar
• Liu Q, Xiong Q, Mei F, et al. Antibody neutralization to SARS-CoV-2 and variants after 1 year in Wuhan, China. Innovation (Camb). 2022 Jan 25;3(1):100181.
   PubMedGoogle Scholar
• Cao Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022 Feb;602(7898):657–663.
   PubMed Web of Science ®Google Scholar
• YangYang GX, Yang L, et al. Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections and vaccinees. J Infect. 2022 Apr;84(4):579–613.
   PubMed Web of Science ®Google Scholar
• Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022 Aug;608(7923):593–602.
   PubMed Web of Science ®Google Scholar
• Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, et al. Antibody escape of SARS-CoV-2 omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell. 2022 Jul 7;185(14):2422–2433.
   PubMed Web of Science ®Google Scholar
• Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022 Feb;602(7898):671–675.
   PubMed Web of Science ®Google Scholar
• Liu L, Iketani S, Guo Y, et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2022 Feb;602(7898):676–681.
   PubMed Web of Science ®Google Scholar
• Lusvarghi S, Pollett SD, Neerukonda SN, et al. SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum but evades most convalescent serum and therapeutic antibodies. Sci Transl Med. 2022 May 18;14(645):eabn8543.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kruger N, Schulz S, et al. The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. 2022 Feb 3;185(3):447–456.
   PubMed Web of Science ®Google Scholar
• Carreno JM, Alshammary H, Tcheou J, et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature. 2022 Feb;602(7898):682–688.
   PubMed Web of Science ®Google Scholar
• Ma C, Chen X, Mei F, et al. Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents. Emerg Microbes Infect. 2022 Dec;11(1):567–572.
   PubMed Web of Science ®Google Scholar
• Bowen JE, Addetia A, Dang HV, et al. Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines. Science. 2022 Aug 19;377(6608):890–894.
   PubMed Web of Science ®Google Scholar
• Urbanowicz RA, Tsoleridis T, Jackson HJ, et al. Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection. Sci Transl Med. 2021 Sep;13(609):eabj0847.
   PubMed Web of Science ®Google Scholar
• Kang CK, Shin HM, Choe PG, et al. Broad humoral and cellular immunity elicited by one-dose mRNA vaccination 18 months after SARS-CoV-2 infection. BMC Med. 2022 May 4;20(1):181.
   PubMed Web of Science ®Google Scholar
• Chang-Monteagudo A, Ochoa-Azze R, Climent-Ruiz Y, et al. A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial. Lancet Reg Health Am. 2021 Dec;4:100079.
   PubMedGoogle Scholar
• Wratil PR, Stern M, Priller A, et al. Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern. Nat Med. 2022 Mar;28(3):496–503.
   PubMed Web of Science ®Google Scholar
• Lucas C, Vogels CBF, Yildirim I, et al. Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. Nature. 2021 Dec;600(7889):523–529.
   PubMed Web of Science ®Google Scholar
• Koerber N, Priller A, Yazici S, et al. Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents. Nat Commun. 2022 Jan 10;13(1):153.
   PubMed Web of Science ®Google Scholar
• Ju B, Zhou B, Song S, et al. Potent antibody immunity to SARS-CoV-2 variants elicited by a third dose of inactivated vaccine. Clin Transl Med. 2022 Feb;12(2):e732.
   PubMed Web of Science ®Google Scholar
• Rosati M, Terpos E, Ntanasis-Stathopoulos I, et al. Sequential analysis of binding and neutralizing antibody in COVID-19 convalescent patients at 14 months after SARS-CoV-2 infection. Front Immunol. 2021;12:793953.
   PubMed Web of Science ®Google Scholar
• Andreano E, Paciello I, Pierleoni G, et al. COVID-19 mRNA third dose induces a unique hybrid immunity-like antibody response. bioRxiv. 2022:2022.05.09.491201.
   Google Scholar